NU-LEFLUNOMIDE TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
02-02-2012
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
LEFLUNOMIDE
から入手可能:
NU-PHARM INC
ATCコード:
L04AK01
INN（国際名）:
LEFLUNOMIDE
投薬量:
20MG
医薬品形態:
TABLET
構図:
LEFLUNOMIDE 20MG
投与経路:
ORAL
パッケージ内のユニット:
100
処方タイプ:
Prescription
治療領域:
DISEASE-MODIFYING ANTIRHEUMATIC AGENTS
製品概要:
Active ingredient group (AIG) number: 0140182002; AHFS:
認証ステータス:
CANCELLED (UNRETURNED ANNUAL)
承認日:
2018-03-28
製品の特徴
Page 1 of 62
PRODUCT MONOGRAPH
Pr
NU-LEFLUNOMIDE
LEFLUNOMIDE TABLETS
HOUSE STANDARD
10 MG AND 20 MG
ANTIRHEUMATIC, IMMUNOMODULATOR AGENT
NU-PHARM INC.
DATE OF REVISION:
1165 CREDITSTONE ROAD, UNIT 2
FEBRUARY 2, 2012
VAUGHAN, ONTARIO
L4K 4N7
CONTROL #: 152701
Page 2 of 62
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.....................................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................................3
INDICATIONS AND CLINICAL
USE.................................................................................................3
CONTRAINDICATIONS
......................................................................................................................3
WARNINGS AND
PRECAUTIONS.....................................................................................................5
ADVERSE REACTIONS
....................................................................................................................13
DRUG
INTERACTIONS.....................................................................................................................18
DOSAGE AND
ADMINISTRATION.................................................................................................21
OVERDOSAGE
...................................................................................................................................22
ACTION AND CLINICAL PHARMACOLOGY
...............................................................................23
STORAGE AND
STABILITY.............................................................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................26
PART II: SCIENTIFIC INFORMATION
...........................................................................................27
PHARMACEUTICAL
INFORMATION....................................................................................
完全なドキュメントを読む
